Lokken Investment Group LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 41.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,936 shares of the company's stock after selling 6,263 shares during the period. Lokken Investment Group LLC's holdings in Johnson & Johnson were worth $1,482,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of JNJ. Apollon Financial LLC raised its position in Johnson & Johnson by 17.8% during the first quarter. Apollon Financial LLC now owns 2,452 shares of the company's stock worth $407,000 after acquiring an additional 371 shares during the last quarter. Apollon Wealth Management LLC increased its stake in shares of Johnson & Johnson by 5.3% during the 1st quarter. Apollon Wealth Management LLC now owns 111,072 shares of the company's stock worth $18,420,000 after purchasing an additional 5,572 shares in the last quarter. Hohimer Wealth Management LLC increased its stake in shares of Johnson & Johnson by 12.8% during the 1st quarter. Hohimer Wealth Management LLC now owns 21,911 shares of the company's stock worth $3,634,000 after purchasing an additional 2,481 shares in the last quarter. Transcendent Capital Group LLC grew its holdings in Johnson & Johnson by 8.9% during the 1st quarter. Transcendent Capital Group LLC now owns 1,288 shares of the company's stock valued at $214,000 after buying an additional 105 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in Johnson & Johnson by 17.3% during the 1st quarter. Signaturefd LLC now owns 58,063 shares of the company's stock valued at $9,629,000 after buying an additional 8,544 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Price Performance
JNJ stock opened at $156.91 on Tuesday. The stock has a 50-day moving average price of $153.79 and a two-hundred day moving average price of $154.63. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The company has a market cap of $377.55 billion, a PE ratio of 17.45, a price-to-earnings-growth ratio of 2.14 and a beta of 0.41.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The business had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.
Analyst Ratings Changes
Several analysts have recently issued reports on the company. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Guggenheim reissued a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. Raymond James Financial lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a report on Monday, April 14th. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $171.00.
View Our Latest Stock Report on Johnson & Johnson
Johnson & Johnson Company Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
